-- Wedbush Securities周四在一份报告中指出，AppLovin (APP) 有望在后续季度实现稳步增长，并保持强劲的利润率，这得益于其扩张计划。 该券商表示，AppLovin在移动游戏广告领域保持着强大的竞争优势，其向电子商务以及最终进军联网电视(CTV)领域的扩张预计将有助于抵御长期竞争压力。 Wedbush还表示，AppLovin的“核心游戏业务持续受益于用户获取(UA)的强劲势头”，其“人工智能集成飞轮效应仍然极难被竞争对手大规模复制”。 该公司指出，AppLovin的股价经受住了近期的做空报告和美国证券交易委员会(SEC)的调查，并未受到基本面的影响，并表示对该公司在扩大规模之前完善其电子商务业务的长期战略充满信心。 Wedbush维持对AppLovin股票的“跑赢大盘”评级，目标价为640美元。 AppLovin股价周四下跌1.6%。
Price: $436.43, Change: $-7.01, Percent Change: -1.58%
Financial stocks were higher late Thursday afternoon, with the NYSE Financial Index rising 1.3% and the State Street Financial Select Sector SPDR ETF (XLF) up 0.5%.The Philadelphia Housing Index climbed 1.6%, and the State Street Real Estate Select Sector SPDR ETF (XLRE) added 1.5%.Bitcoin (BTC-USD) rose 0.9% to $76,409, and the yield for 10-year US Treasuries decreased 2.8 basis points to 4.39%.In corporate news, AvalonBay Communities (AVB) and Equity Residential (EQR) have held discussions over a potential merger, which would be one of the biggest real estate deals ever, Bloomberg reported. AvalonBay shares were down 1.1%, and Equity Residential was fractionally lower.
Meta Platforms (META) CEO Mark Zuckerberg and Apple (AAPL) CEO Tim Cook are not pursuing a bid for the National Football League's Seattle Seahawks, Bloomberg reported on Thursday, citing company and industry sources.A Meta spokesperson said Zuckerberg is not making any investment or bid for the team, while a person familiar with Cook's plans denied his involvement, the report said.Meta and Apple did not immediately respond to requests for comment from.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: $616.43, Change: $-52.69, Percent Change: -7.87%
Axsome Therapeutics (AXSM) said Thursday the US Food and Drug Administration approved Auvelity for the treatment of agitation associated with Alzheimer's disease dementia.The approval was supported by two phase 3 clinical trials that showed the drug significantly improved agitation symptoms and resulted in a longer time to relapse compared with placebo.The medication acts on N-methyl-D-aspartate and sigma-1 receptors in the brain and is also approved for adults with major depressive disorder, the company added.Shares of Axsome were up more than 12% in Thursday trading.Price: $206.45, Change: $+22.50, Percent Change: +12.23%